Paul J. Coleman

Paul J. Coleman

Auto-generated profile, based on publicly available information

Paul J. Coleman

Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA 19486, USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2019 in Science
Verified
Journal Article
Closed access
PDF file
KCKevin R. Campos
Kevin R. Campos
PCPaul J. Coleman
Paul J. Coleman
JAJuan C. Alvarez
Juan C. Alvarez
SDSpencer D. Dreher
Spencer D. Dreher
RGRobert M. Garbaccio
Robert M. Garbaccio
EPEmma R. Parmee
Emma R. Parmee
Synthetic innovation in drug development: Chemical synthesis plays a key role in pharmaceutical research and development. Campos et al. review some of the advantages that have come from recent innovations in synthetic methods. In particular, they highlight small-molecule catalysts stimulated by visible light, enzymes engineered for versatility beyond their intrinsic function, and bio-orthogonal reactions to selectively modify proteins for conjugation. High-throughput techniques are also poised to accelerate methods optimization from small-scale discovery to large-scale production, and complementary machine-learning approaches are just coming into focus. Science , this issue p. eaat0805

6 January 2017 in Annual Review of Pharmacology and Toxicology
Verified
Journal Article
Closed access
PCPaul J. Coleman
Paul J. Coleman
AGAnthony L. Gotter
Anthony L. Gotter
WHW. Joseph Herring
W. Joseph Herring
CWChristopher J. Winrow
Christopher J. Winrow
JRJohn J. Renger
John J. Renger
Historically, pharmacological therapies have used mechanisms such as γ-aminobutyric acid A (GABAA) receptor potentiation to drive sleep through broad suppression of central nervous system activity. With the discovery of orexin signaling loss as the etiology underlying narcolepsy, a disorder associated with hypersomnolence, orexin antagonism emerged as an alternative approach to attenuate orexin-induced wakefulness more selectively. Dual orexin receptor antagonists (DORAs) block the activity of orexin 1 and 2 receptors to both reduce the threshold to transition into sleep and attenuate orexin-mediated arousal. Among DORAs evaluated clinically, suvorexant has pharmacokinetic properties engineered for a plasma half-life appropriate for rapid sleep onset and maintenance at low to moderate doses. Unlike GABAAreceptor modulators, DORAs promote both non-rapid eye movement (NREM) and REM sleep, do not disrupt sleep stage–specific quantitative electroencephalogram spectral profiles, and allow somnolence indistinct from normal sleep. The preservation of cognitive performance and the ability to arouse to salient stimuli after DORA administration suggest further advantages over historical therapies.

3 February 2012 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
PCPaul J. Coleman
Paul J. Coleman
JSJohn D. Schreier
John D. Schreier
CCChristopher D. Cox
Christopher D. Cox
DWDavid B. Whitman
David B. Whitman
MBMichael J. Bogusky
Michael J. Bogusky
JRJohn J. Renger
John J. Renger

7 January 1997 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
DEDavid A. Evans
David A. Evans
PCPaul J. Coleman
Paul J. Coleman
LDLuiz Carlos Dias
Luiz Carlos Dias

28 August 2013 in BMC Neuroscience
Verified
Journal Article
Open access
PDF file
AGAnthony L Gotter
Anthony L Gotter
CWChristopher J Winrow
Christopher J Winrow
JBJoseph Brunner
Joseph Brunner
SGSusan L Garson
Susan L Garson
SFSteven V Fox
Steven V Fox
JRJohn J Renger
John J Renger
Background: Drugs targeting insomnia ideally promote sleep throughout the night, maintain normal sleep architecture, and are devoid of residual effects associated with morning sedation. These features of an ideal compound are not only dependent upon pharmacokinetics, receptor binding kinetics, potency and pharmacodynamic activity, but also upon a compound’s mechanism of action. Results: Dual orexin receptor antagonists (DORAs) block the arousal-promoting activity of orexin peptides and, as demonstrated in the current work, exhibit an efficacy signal window dependent upon oscillating levels of endogenous orexin neuropeptide. Sleep efficacy of structurally diverse DORAs in rat and dog was achieved at plasma exposures corresponding to orexin 2 receptor (OX2R) occupancies in the range of 65 to 80%. In rats, the time course of OX2R occupancy was dependent upon receptor binding kinetics and was tightly correlated with the timing of active wake reduction. In rhesus monkeys, direct comparison of DORA-22 with GABA-A modulators at similar sleep-inducing doses revealed that diazepam produced next-day residual sleep and both diazepam and eszopiclone induced next-day cognitive deficits. In stark contrast, DORA-22 did not produce residual effects. Furthermore, DORA-22 evoked only minimal changes in quantitative electroencephalogram (qEEG) activity during the normal resting phase in contrast to GABA-A modulators which induced substantial qEEG changes. Conclusion: The higher levels of receptor occupancy necessary for DORA efficacy require a plasma concentration profile sufficient to maintain sleep for the duration of the resting period. DORAs, with a half-life exceeding 8 h in humans, are expected to fulfill this requirement as exposures drop to sub-threshold receptor occupancy levels prior to the wake period, potentially avoiding next-day residual effects at therapeutic doses.

14 August 2003 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
DEDavid A. Evans
David A. Evans
BCBernard Côté
Bernard Côté
PCPaul J. Coleman
Paul J. Coleman
BCBrian T. Connell
Brian T. Connell